Paracoccidioidomycosis (South American blastomycosis): treatment with miconazole.
Six patients with multisystem paracoccidioidomycosis proven by serology and culture or smear were treated with relatively brief courses of intravenous miconazole. Two had relapsed following prior therapy; 6 had active pulmonary, 4 laryngeal, 2 oropharyngeal, 2 lymphoid, and 1 abdominal disease. Paracoccidioides brasiliensis was highly susceptible to miconazole in vitro; minimal inhibitory concentration was less than or equal to 0.001 microgram/ml. Clinical examination showed a prompt and objective response in all patients, confirmed by smear or culture and X-rays; in 4/6 serological response was shown. Side effects were minor. Two patients relapsed 3--5 mo after therapy; another had a rise in antibody 6 mo after therapy and was given maintenance oral sulfa. One remains in remission 7 mo after treatment; two given oral sulfa after response to miconazole remain in remission 4--6 mo after treatment. Paracoccidioidomycosis responds well to miconazole, but longer courses may be needed to prevent relapse.
D000293:Adolescent; D000328:Adult; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008825:Miconazole / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010229:Paracoccidioidomycosis / Q000188:drug therapy* / Q000276:immunology
D007093:Imidazoles; D008825:Miconazole